7904results about "Liposomal delivery" patented technology

The present disclosure generally relates to liposomal compositions comprising an ATR inhibitor and uses thereof for treating various diseases and disorders. In one aspect, the use relates to methods of treating cancer, such as pancreatic cancer, breast cancer, and lung cancer.

A method for treating, inhibiting, or ameliorating cancer, such as KRAS-mutant cancer, including administering a GST-p inhibitor and either a KRAS inhibitor or a chemotherapy drug in therapeutically effective amounts to a subject suffering from the cancer in need thereof.

The invention provides stabilizing agents, compositions, methods of manufacturing, and uses thereof. In one aspect, a lipid nanoparticle composition includes: (a) an ionizable lipid; (b) two or more lipids; and (c) a stabilizing agent of formula (I) or formula (II) and methods for preparing the stabilizing agents and the lipid nanoparticle are provided.

The invention provides stabilizing agents, compositions, methods of manufacturing, and uses thereof. In one aspect, a lipid nanoparticle composition including: (a) an ionizable lipid; (b) two or more lipids; and (c) a stabilizing agent of formula (I) and a method for preparing the stabilizing agent and the lipid nanoparticle are provided.

The invention provides stabilizing agents, compositions, methods of manufacturing, and uses thereof. In one aspect, a lipid nanoparticle composition includes: (a) an ionizable lipid; (b) two or more lipids; and (c) a stabilizing agent of formula (I) and a method for preparing the stabilizing agent and the lipid nanoparticle are provided.

Compounds are provided having the following structure:or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8, R9, L1, L2, a, b, c, d and e are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

The present disclosure provides compounds according to Formulae I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIII, and XIV for use as a component in a lipid nanoparticle composition for the delivery of biological and / or therapeutic agents. The present disclosure also provides novel, stable lipid nanoparticle compositions comprising one or more biological and / or therapeutic agents, as well as methods of making and delivering lipid nanoparticle compositions.

The present disclosure provides humanized antibodies and antigen binding domains thereof that bind CD8α and other antibody formats comprising these antigen binding domains, their use as a targeting moiety on lipid nanoparticles (tLNP) to deliver a therapeutic payload (such as a nucleic acid molecule) or other types of payloads. The present disclosure further relates to pharmaceutical compositions comprising the humanized anti-CD8α antibodies and CD8-targeted tLNP encapsulating a payload.

Disclosed are compositions of lipid nanoparticles (LNP) comprising an ionizable cationic lipid, a phospholipid, a sterol, and a PEG-lipid (non-functionalized and optionally functionalized). The functionalized PEG-lipid can be conjugated with a binding moiety to create a targeted LNP (tLNP). The disclosed tLNP preferentially deliver a nucleic acid molecule or other negatively charged payload to cells expressing a cell surface antigen recognized by the binding moiety of the tLNP, and are better tolerated, as compared to LNPs and tLNPs comprising ionizable cationic lipids found in marketed pharmaceuticals comprising LNPs.

Disclosed are compositions of lipid nanoparticles (LNP) comprising an ionizable cationic lipid, a phospholipid, a sterol, and a PEG-lipid (non-functionalized and optionally functionalized). The functionalized PEG-lipid can be conjugated with a binding moiety to create a targeted LNP (tLNP). The disclosed tLNP preferentially deliver a nucleic acid molecule or other negatively charged payload to cells expressing a cell surface antigen recognized by the binding moiety of the tLNP, and are better tolerated, as compared to LNPs and tLNPs comprising ionizable cationic lipids found in marketed pharmaceuticals comprising LNPs.

The invention discloses a ginsenoside liposome. The ginsenoside liposome comprises ginsenoside, phospholipid and a surfactant, and the ginsenoside comprises protopanoxadiol or / and protopanaxatriol. The invention also discloses a preparation method of the ginsenoside liposome and application of the ginsenoside liposome in preparation of medicines, cosmetics or skin care products. According to the invention, the final desugared product of ginsenoside with the effect of treating skin toxicity reaction is prepared into the liposome, so that the membrane permeation and absorption capabilities of ginsenoside are greatly improved, the skin toxicity caused by tumor treatment can be quickly and effectively relieved, and the drug effect can be played for a long time; the invention provides a new method for treating skin toxic reaction caused by tumor treatment, and makes up for the requirements which cannot be met by the existing treatment means.

The invention provides a preparation method of mitochondria-targeted antioxidant hybrid vesicles. The preparation method comprises the following steps: S1, preparing and separating adipose-derived stem cell nano-vesicles; s2, preparing a liposome loaded with dihydromyricetin and distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-triphenylphosphine targeting peptide by an ethanol injection method; and S3, preparing the hybrid nano vesicles loaded with the dihydromyricetin and the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-triphenylphosphine targeting peptide. The invention also provides the hybrid vesicles prepared by the method and application of the hybrid vesicles in preparation of refractory diabetes wound treatment drugs. The lipidosome and the adipose-derived stem cell nano-vesicles are hybridized to prepare the hybridized vesicles capable of targeting mitochondria and resisting oxidation, the hybridized vesicles are applied to wound treatment for the first time, the problem of oxidative stress of diabetic wounds is solved, wound healing is accelerated, and a new strategy is provided for optimizing mitochondrial function defects and oxidative stress of the diabetic wounds.

Provided herein are lipids having the Formula I or Formula Ia:and pharmaceutically acceptable salts thereof, wherein R′, R1, R2, R3, R4, R5, R6a, R6b, X1, X2, and n are as defined herein for Formula I and Formula Ia, respectively. Also provided herein are lipid nanoparticle (LNP) compositions comprising lipid having the Formula I or Ia and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).

Compounds are provided having the following structure:or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein a, b, c, d, G1, G2, L1, L2, R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8 and X are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, nanoparticles comprising the compounds and methods for their use and preparation are also provided.

The present disclosure provides lipid nanoparticle compositions comprising a nucleic acid encoding a therapeutic polypeptide. The disclosure also provides novel IL-15 polypeptides, fusion proteins comprising the IL-15 polypeptides, and nucleic acids encoding the IL-15 polypeptides and the fusion proteins.

Embodiments of the present disclosure relates to a new and improved large scale commercial manufacturing process of making bupivacaine multivesicular liposomes (MVLs). Batches of bupivacaine MVLs prepared by the new process have high yields, improved stabilities, and desired particle size distributions.

Embodiments of the present disclosure relates to commercial manufacturing process of making bupivacaine multivesicular liposomes with improved yield and desired particle size distribution.

The invention relates to the technical field of pharmaceutical chemicals, and discloses sequential drug release liposome hydrogel and a preparation method and application thereof, and the preparation method of the liposome hydrogel comprises the following steps: step 1, preparation of drug-loaded positive charge liposome; step 2, preparing phenylboronic acid modified polysaccharide; and step 3, carrying out vortex mixing on the drug-loaded positive charge liposome solution, the phenylboronic acid modified polysaccharide hydrogel precursor powder and the spermidine solution to obtain the liposome hydrogel. According to the sequential drug release liposome hydrogel as well as the preparation method and the application thereof, the liposome hydrogel is prepared by taking high-molecular hyaluronic acid and phenylboronic acid as main raw materials, and the liposome hydrogel has microenvironment responsiveness and time-space characteristics of drug release, and can be used for treating osteoarthritis in an environment with active oxygen increase, so that the drug release effect is good, and the drug release effect is good. The functions of early-stage anti-inflammation and continuous cartilage regeneration are achieved by sequentially releasing double drugs, synovitis can be effectively relieved, cartilage regeneration can be promoted, and the compound can be used for preparing drugs for treating osteoarthritis.

Embodiments of the present disclosure relates to a new and improved large scale commercial manufacturing process of making bupivacaine multivesicular liposomes (MVLs). Batches of bupivacaine MVLs prepared by the new process have high yields, improved stabilities, and desired particle size distributions.

The present invention relates to sonosensitive liposomes and a method for preparing the same. The sonosensitive liposomes according to the present invention improve the delivery efficiency of encapsulated drugs, and are expected to exhibit various functions in the fields of cancer treatment and drug delivery carriers by improving drug delivery effects through targeted cancer cells when used in combination with ultrasonic treatment.

The present disclosure relates to a copolymer and a polymersome for targeted delivery of biomolecules to a living organism. The exemplary copolymer comprises an initiator block, a propagator block, and a linkage connecting the initiator block and the propagator block. The initiator block comprises a glycan head configured to provide a targeted delivery, and the propagator block comprises a functional moiety configured to provide desired properties for the polymersome.

The invention discloses a liver-targeting drug liposome and application thereof, and relates to the field of drug delivery, cholate and mannose are used for respectively modifying phospholipid molecules DSPE-PEG2000, two raw materials DSPE-PEG2000-CA and DSPE-PEG2000-MAN composed of the liposome are synthesized, and then the liposome is prepared into the liver-targeting drug liposome. The liposome with liver targeting property is obtained from the liposome, cholesterol, DSPC, DC-cholesterol and a water-soluble therapeutic drug according to a certain proportion, the liposome has relatively high cell safety and liver targeting property, and the therapeutic effect of the corresponding drug can be remarkably improved after the drug is embedded.

The disclosure provides ionizable lipids for constructing lipid nanoparticles. The disclosure further provides conjugates comprising a targeting moiety a lipid nanoparticle (LNP) encapsulating a therapeutic agent (i.e., payload) for delivery to immune cells or hematopoietic stem cells (HSCs). The conjugates can be formulated in a pharmaceutical composition and can be directly administered to a patient in need of (i.e. in vivo administration).

The invention provides an immunologic adjuvant composition as well as a preparation method and application thereof. The immunologic adjuvant composition comprises an immunologic active agent and a liposome for loading the immunologic active agent, wherein the immunologic active agent comprises saponin and CpG oligodeoxynucleotide. The immunologic adjuvant composition can induce immune response of mammals to human herpes virus and / or hepatitis B virus, and can induce generation of a relatively high cellular immune response level. The QS21 and the CpG oligodeoxynucleotide are simultaneously loaded by using the liposome, so that the QS21 and the CpG oligodeoxynucleotide have a better synergistic effect in the aspect of promoting cellular immunity, and compared with a Shingrix commercially available vaccine, the vaccine can induce generation of a higher cellular immune response level.

The present disclosure provides bispecific stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., immune effector cells such as T cells, B cells, natural killer cells, and dendritic cells, to modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.

The present disclosure relates to a copolymer and a polymersome for targeted delivery of biomolecules to a living organism. The exemplary copolymer comprises an initiator block, a propagator block, and a linkage connecting the initiator block and the propagator block. The initiator block comprises a glycan head configured to provide a targeted delivery, and the propagator block comprises a functional moiety configured to provide desired properties for the polymersome.

The invention provides a composition for promoting hair regeneration after chemotherapy as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: modifying the surface of a gold nanocage with polydopamine, loading the modified gold nanocage on an exosome, complexing magnesium ions and zinc ions to prepare a modified exosome, preparing a nano drug-loaded liposome from curcumin, resveratrol and epigallocatechin gallate, mixing the nano drug-loaded liposome with the modified exosome to prepare a multi-layer liposome, and preparing the multi-layer liposome from the nano drug-loaded liposome. And mixing with a penetration enhancer, and adding into a temperature-sensitive hydrogel system to prepare the composition for promoting hair regeneration after chemotherapy. The composition for promoting hair regeneration after chemotherapy has a good transdermal absorption promoting effect, can slowly release drugs, promotes hair follicles to be converted from a resting stage to a growing stage under the synergistic effect of the drugs, regulates and controls multiple pathways (such as anti-apoptosis, angiogenesis promotion and anti-inflammation) at the same time, is matched with a complex pathological mechanism of hair regeneration after chemotherapy, and can promote hair regeneration after chemotherapy. Wide application prospects are realized.

The present disclosure relates to a low glycosylated spike protein and a vaccine designed to express the spike protein in vivo. The present disclosure also teaches a method for generating an immune response by utilizing the low glycosylated spike protein, which provides a broader protection across different variants. A method for identifying a glycan-shielded conserved peptide of a glycoprotein is also disclosed.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a targeted liposome as an active component in preparation of a medicine for treating ischemic brain injury. The targeted lipidosome for treating cerebral arterial thrombosis is prepared by fusing the lipidosome and the platelet-neutrophil aggregate membrane, realizes efficient and specific targeting of an ischemic brain region, effectively reduces brain tissue infarction and damage of a new region, relieves brain inflammation through multi-channel regulation and control, and improves the cerebral arterial thrombosis treatment effect. The compound can be used as an active ingredient for preparing a medicine for treating ischemic brain injury. And after the target liposome is further coated with a rutin drug, the synergistic treatment effect is realized. The liposome medicine can be used as an active component and has a good application prospect in treatment of ischemic brain injury diseases.